Partial
Needs Improvement
Patient Risk:
Moderate
Summary
Several safety-related statements are partially supported (half-life, GH lowering/monitoring context, gallstones, and glucose dysregulation incidence), but many administration/timing, missed-dose, and drug-spacing claims are not supported by the provided label text, indicating substantial label nonconformance.
Category Scores
Accurate Statements
Sandostatin has a short half-life.
12.3 Pharmacokinetics (Elimination): apparent half-life of 1.7 to 1.9 hours
Sandostatin lowers growth hormone.
12.1 Mechanism of Action (potent inhibitor of GH); 2.2 Recommended Dosage and Monitoring for Acromegaly (goal GH < 5 ng/mL)
Gallstones are a common side effect concern with Sandostatin.
5.2 Cholelithiasis and Complications of Cholelithiasis: incidence of biliary tract abnormalities 63% (27% gallstones)
Changes in blood sugar are a common side effect concern with Sandostatin.
5.3 Hyperglycemia and Hypoglycemia: hyperglycemia 16% and hypoglycemia 3% in acromegalic patients
Gallbladder problems can appear after months of use with Sandostatin.
5.2 Cholelithiasis and Complications of Cholelithiasis: incidence of stones or sludge is higher with 12 months or longer (52%)
Unsupported Statements
Most people take Sandostatin at the same time each day.
Not supported in provided label sections.
Steady levels of Sandostatin help control symptoms.
Not supported in provided label sections.
For daily injections, doctors often recommend evening doses.
Not supported in provided label sections.
Evening dosing is recommended so any stomach upset or injection-site reactions happen while the patient sleeps.
Not supported in provided label sections.
Sandostatin LAR is given every four weeks by a healthcare provider.
Not supported in provided label sections (no LAR interval included in provided text).
With Sandostatin LAR, timing is less critical than for daily dosing.
Not supported in provided label sections.
Patients still prefer a consistent day of the month with Sandostatin LAR.
Not supported in provided label sections.
Sandostatin slows digestion.
Not supported in provided label sections.
Taking Sandostatin on an empty stomach can increase nausea.
Not supported in provided label sections.
Taking Sandostatin with food may reduce nausea for some patients.
Not supported in provided label sections.
Shifting the timing of Sandostatin by more than a couple of hours can change how well symptoms are controlled.
Not supported in provided label sections.
Sandostatin reduces stomach acid.
Not supported in provided label sections.
Sandostatin should be separated from oral drugs that need stomach acid for absorption.
Not supported in provided label sections.
Certain antifungals require stomach acid for absorption.
Not supported in provided label sections.
Certain HIV medicines require stomach acid for absorption.
Not supported in provided label sections.
It is recommended to check with a pharmacist for specific spacing with other oral drugs.
Not supported in provided label sections.
If a dose of Sandostatin is missed, take it as soon as remembered unless it is almost time for the next dose.
Not supported in provided label sections.
Do not double up if a dose of Sandostatin is missed.
Not supported in provided label sections.
Missing doses of Sandostatin can cause a sudden return of flushing.
Not supported in provided label sections.
Missing doses of Sandostatin can cause a sudden return of diarrhea.
Not supported in provided label sections.
Novartis manufactures both the daily and long-acting forms of Sandostatin.
Not supported in provided label sections.
U.S. patents for the long-acting formulation expired years ago.
Not supported in provided label sections.
Several generic versions of the long-acting formulation are now available.
Not supported in provided label sections.
Daily subcutaneous injections give tighter control for people with rapidly changing symptoms.
Not supported in provided label sections.
Monthly intramuscular Sandostatin LAR is more convenient.
Not supported in provided label sections.
Monthly intramuscular Sandostatin LAR can take several weeks to reach steady levels.
Not supported in provided label sections.
Some patients start on daily shots first.
Not supported in provided label sections.
Injection-site pain is a common side effect concern with Sandostatin.
Not supported in provided label sections.
Doctors order regular ultrasounds for gallbladder monitoring after months of Sandostatin use.
Not supported in provided label sections.
Contradictions
Important Omissions
Dose adjustment/monitoring specifics for missing-dose management and administration instructions are not verifiable from the provided label excerpts; the evaluated content included specific missed-dose instructions without label support.
Importance:
Moderate
Drug interaction content in the label excerpt provided relates to CYP3A4/low therapeutic index drugs used with caution; the evaluated claims focused on stomach-acid-related spacing and specific antifungals/HIV medicines, which are not present in the supplied label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims about administration timing, missed-dose handling, and specific drug-spacing (stomach-acid related) were not supported by the provided label text, which could lead to dosing/interaction misunderstandings not grounded in the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Improvement
Primary Issue
Large portion of claims regarding dosing/timing, missed-dose instructions, and stomach-acid-related drug spacing are not supported by the provided label sections.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label excerpts (e.g., half-life range, GH suppression/monitoring goals for acromegaly, gallbladder complication incidence, glucose monitoring, and CYP3A4 low therapeutic index drug caution). Remove or rephrase unsupported statements.